時代中國控股(01233.HK)擬發行2.5億美元優先票據
格隆匯 10 月 23日丨時代中國控股(01233.HK)發佈公告,2020年10月22日,公司及附屬公司擔保人與瑞銀、瑞信、德意志銀行、中信里昂證券、中信銀行(國際)、花旗、民銀資本、國泰君安國際、海通國際、匯豐及東亞銀行有限公司就發行額外於2025年到期的2.5億美元6.75%優先票據(將與於2025年到期的3億美元6.75%優先票據合併並組成一個單一系列)訂立購買協議。
公司擬將額外票據發行所得款項淨額用作其若干現有債務再融資。公司或會因應不斷變化的市況而調整其計劃,因此或會重新分配所得款項淨額用途。公司將尋求額外票據於聯交所上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.